vgb-r04
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05152732)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Coagulation factor IXACTIVATOR
F9 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05441553 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2022 | Chinese Academy of Medical Sciences, Shanghai Vitalgen BioPharma Co., Ltd. |
| NCT05152732 | Early Phase 1 (Phase 1) | Dec 31, 2021 | Chinese Academy of Medical Sciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 1 | 2 | 2021 |
| Shanghai Vitalgen BioPharma Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1